HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results on Thursday, underscoring progress in the commercial launch of its FDA-cleared cardiac monitoring platform. The company announced initial commercial partnerships in key U.S. markets and noted advancements in its heart attack detection and ambulatory ECG patch initiatives. HeartBeam also completed an April public offering that raised $11.5 million in gross proceeds to support its growth plans.
The Los Angeles-based medical technology company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the same period last year. Research and development expenses declined year over year as HeartBeam shifted focus toward commercialization of its platform, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology.
HeartBeam’s platform is designed to be the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology is intended for portable use, allowing physicians to monitor cardiac health trends and detect acute conditions outside medical facilities. The company aims to redefine cardiac health management by delivering actionable heart intelligence wherever the patient is.
The full press release is available at https://ibn.fm/guMCF. For more details on the cleared indications for use, visit https://www.heartbeam.com/indications. The latest news and updates regarding HeartBeam can be found in the company’s newsroom at https://ibn.fm/BEAT.
HeartBeam’s results come as the company advances its commercial strategy in a competitive cardiac monitoring market. The improved net loss and reduced R&D spending reflect a transition from development to revenue generation. The $11.5 million public offering provides additional capital to support partnerships and market expansion. For investors and healthcare providers, the company’s progress signals potential shifts in how cardiac conditions are detected and managed remotely.
Forward-looking statements in the release are subject to risks and uncertainties, as detailed in HeartBeam’s filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.
